4/A: Haemonetics Executive Amends SEC Filing, Correcting Equity Award Amounts

Haemonetics Corp's EVP, Chief Commercial Officer Roy Galvin, filed an amended Form 4 to correct previously reported Restricted Stock Units and Non-qualified Stock Options.

Summary

• Roy Galvin, EVP, Chief Commercial Officer of Haemonetics Corp (HAE), filed an amended Form 4 (4/A) to correct errors in a previous filing dated May 20, 2025.
• The amendment corrects the number of Restricted Stock Units (RSUs) awarded from 6,755 to 5,689, a net decrease of 1,066 RSUs.
• The amendment also corrects the number of Non-qualified Stock Options awarded from 14,626 to 12,317, a net decrease of 2,309 options.
• Following these corrections, Mr. Galvin beneficially owns 12,932 shares of Common Stock, which includes unvested RSUs.
• He also beneficially owns 12,317 Non-qualified Stock Options with an exercise price of $70.31, expiring on May 16, 2032.
• The RSUs vest in three equal annual installments beginning on the first anniversary of the grant date.
• The options vest in annual increments of 25% beginning on the first anniversary of the grant date.

Sentiment

Score: 5

Explanation: The document is an administrative correction of previously reported executive equity awards. While the correction itself indicates an initial error and the corrected amounts are lower, it does not reflect a fundamental change in the company's operations or financial health, making its sentiment neutral.

Positives

• The executive, Roy Galvin, received significant equity awards (5,689 Restricted Stock Units and 12,317 Non-qualified Stock Options), aligning his interests with shareholders.
• The company demonstrates transparency by filing an amendment to correct administrative errors in its disclosures.

Negatives

• The initial filing contained errors, necessitating an amendment.
• The corrected amounts for both Restricted Stock Units and Non-qualified Stock Options are lower than initially reported, indicating a reduction in the executive's previously disclosed equity awards.

Risks

• Potential for administrative errors in financial reporting, though this specific correction appears minor and has been addressed.

Future Outlook

Future filings by the reporting person will reflect the corrected amounts of Restricted Stock Units and Non-qualified Stock Options. The granted Restricted Stock Units will vest in three equal annual installments, and the Non-qualified Stock Options will vest in annual increments of 25%, both beginning on the first anniversary of their grant date.

Management Comments

• "On May 20, 2025, the reporting person filed a Form 4 that incorrectly showed the amount of RSUs awarded to be 6,755 instead of 5,689. This net decrease of 1,066 RSUs, and the corresponding change in securities beneficially owned by the reporting person, will be reflected in future filings by the reporting person."
• "On May 20, 2025, the reporting person filed a Form 4 that incorrectly showed the amount of options awarded to be 14,626 instead of 12,317. This net decrease of 2,309 options will be reflected in future filings by the reporting person."

Industry Context

This filing represents a standard amendment to an insider trading report, common in publicly traded companies to ensure accurate disclosure of executive equity compensation. The grant of RSUs and stock options is a typical component of executive incentive plans across various industries, aiming to align management's interests with long-term shareholder value.

Comparison to Industry Standards

• This document does not provide sufficient detail on the overall compensation package or performance metrics to allow for a specific comparison to industry standards or comparable companies. It solely focuses on an administrative correction of previously reported equity awards.

Stakeholder Impact

• Shareholders: Provides accurate disclosure of executive equity compensation, correcting previous errors. The reduction in reported awards is minor and administrative.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• Future SEC filings by the reporting person will reflect the corrected amounts of beneficially owned securities.
• The granted Restricted Stock Units will vest in three equal annual installments beginning on the first anniversary of the grant date.
• The granted Non-qualified Stock Options will vest in annual increments of 25% beginning on the first anniversary of the grant date.

Key Dates

Keywords

Haemonetics Corp, HAE, SEC Form 4/A, insider trading, beneficial ownership, restricted stock units, stock options, executive compensation, equity awards, Roy Galvin